Highlights

  • ReNerve said the Align clinical study is recruiting its final patients, with data expected to be published and presented in late 2026 or early 2027.
  • The study includes two 120-patient cohorts comparing standard neurectomy repair with repair protected by the NervAlign Nerve Cuff.
  • Interim pain-score data presented by the company showed a larger reduction in the NervAlign group than in the standard-care group, while final analysis remains pending.
  • ReNerve continues to expand the commercial reach of its nerve-repair products while progressing additional devices through development.

ReNerve Limited (ASX:RNV) is an Australian medical device company focused on products for peripheral nerve injury repair. In its 2026 AGM presentation, the company said recruitment for the Align clinical study of its NervAlign Nerve Cuff is nearing completion, with final study data expected to be published and presented in late 2026 or early 2027.

Align Study Moves Toward Final Recruitment

The Align study is designed around two cohorts of 120 patients each. One group receives standard neurectomy repair, while the test group receives neurectomy repair with NervAlign Nerve Cuff protection. ReNerve said the primary focus is statistically significant pain reduction, with secondary measures covering patient recovery and product performance during surgery. Follow-up is conducted about six to nine months after the operation.

Interim Pain Data Presented by ReNerve

The company presented interim pain-score comparisons from the study. In the standard-care group, the reported pain score declined from 7.1 to 3.3, which ReNerve described as a 54% improvement. In the NervAlign group, the score declined from 7.1 to 0.4, described by the company as a 95% improvement. These figures are interim company-reported results rather than the final published study outcome, so the complete analysis remains pending.

NervAlign Commercial Position

ReNerve said NervAlign is bio-absorbed within six months, is semi-translucent and can be secured with sutures, glue or micro clips, or used without fixation. The company also stated that the product does not require a change to surgical technique. Hundreds of patients have been implanted to date, and the company reported commercial activity through 25 US distributors and two direct sales representatives, alongside distribution activity across several Asian markets.

Product Pipeline Continues to Develop

Beyond NervAlign, ReNerve is developing three nerve conduits as well as a Nerve Protector, Nerve Cap and Nerve Guide Matrix. The company said the Nerve Guide Matrix is at stage three of four, with the regulatory pathway confirmed and good Manufacturing practice and commercial-scale manufacturing identified as the next step. Other research-stage programs include a nerve stimulator, platelet-rich plasma work and an exosome collaboration. No regulatory decision dates were provided in the presentation.

Other 2026 Corporate Updates

ReNerve reported that all 16 resolutions at its 2026 Annual General Meeting were carried. On 6 October 2026, it also gave notice of the proposed issue of 228,345 ordinary shares valued at $17,309 in total in lieu of cash payment for services. The issue was stated to use the company's existing Placement capacity.

Key Insights

The near-completion of patient recruitment places the Align study closer to a full data readout, while the company continues commercial activity and development of additional nerve-repair products. The main near-term milestone identified by ReNerve is publication and presentation of the Align study data in late 2026 or early 2027. Until the final analysis is released, the interim pain results remain preliminary and should be read in that context.